# INHERITED INFERTILITY - MAPPING LOCI ASSOCIATED WITH IMPAIRED FEMALE REPRODUCTION

Sanni Ruotsalainen<sup>1</sup>, Juha Karjalainen<sup>1,2,3,4,5</sup>, Mitja Kurki<sup>1,2,3,4,5</sup>, Elisa Lahtela<sup>1</sup>, Matti Pirinen<sup>1,6,7</sup>, Juha Riikonen<sup>1</sup>, Jarmo Ritari<sup>8</sup>, Silja Tammi<sup>8</sup>, Jukka Partanen<sup>8</sup>, Hannele Laivuori<sup>1,9,10,11</sup>, FinnGen\*, Aarno Palotie<sup>1,2,3,4,5,12</sup>, Henrike Heyne<sup>1,2,13,14,15</sup>, Mark Daly<sup>1,2,3,4,5</sup>, Elisabeth Widen<sup>1\*\*</sup>

- 1) Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
- Program for Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 3) Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- 4) Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
- 5) Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
- 6) Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland
- 7) Department of Public Health, University of Helsinki, Helsinki, Finland
- 8) Finnish Red Cross Blood Service, R&D, Helsinki, Finland
- 9) Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- 10) Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland
- 11) Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, University of Tampere, Tampere, Finland
- 12) Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
- 13) Digital Health Center, Hasso Plattner Institute for Digital Engineering, University of Potsdam, Potsdam, Germany
- 14) Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 15) Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- \* A full list of the FinnGen research team members appears at the end of the paper.

\*\*Corresponding author

E-mail: elisabeth.widen@helsinki.fi

### **ABSTRACT**

Female infertility is a common and complex health problem affecting millions of women worldwide. While multiple factors can contribute to this condition, the underlying cause remains elusive in up to 15-30% of cases. In our large genomewide association study (GWAS) of 22,849 women with infertility and 198,989 controls from the Finnish population cohort FinnGen, we unveil a unique landscape of genetic factors associated with the disease. Our recessive analysis identified a lowfrequency stop-gained mutation in TBPL2 (p.Arg331Ter; minor allele frequency (MAF) = 1.2%) with an impact comparable to highly penetrant monogenic mutations  $(OR = 650, p = 4.1 \times 10^{-25})$ . While previous studies have linked the homologous gene to anovulation and sterility in knockout mice, the severe consequence of the p.Arg331Ter mutation was evidenced by homozygous carriers having significantly fewer offspring (average of 0.16) compared to women belonging to the other genotype groups (average of 1.75 offspring,  $p = 1.4 \times 10^{-15}$ ). Notably, all homozygous women who had given birth had received infertility therapy. Moreover, our agestratified analyses identified three additional genome-wide significant loci. Two loci were associated with early-onset disease (infertility diagnosed before age 30), located near CHEK2 and within the major histocompatibility complex (MHC) -region. The third locus, associated with late-onset disease, had its lead SNP located in an intron of a IncRNA gene. Taken together, our data highlight the significance of rare recessive alleles in shaping female infertility risk. The results further provide evidence supporting specific age-dependent mechanisms underlying this complex disorder.

### INTRODUCTION

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Infertility affects millions of individuals of reproductive age worldwide. WHO estimates that the lifetime prevalence of infertility in the Americas and Europe is 20% and 16.5%, respectively. Although infertility may stem from factors related both to women and men, it is commonly attributed to female factors, either entirely or in part.<sup>2</sup> Ovarian dysfunction is a prevalent underlying reason, and age-related infertility is also on the rise due to delayed childbirth. Yet in 15-30% of cases, the cause of infertility remains unexplained despite thorough clinical investigation.<sup>2,3</sup> Certain pre-existing conditions, such as polycystic ovarian syndrome (PCOS), endometriosis, and uterine fibroids, are associated with increased infertility risk in women. Genome-wide association studies (GWAS) have identified 20, 40, and 30 common variant loci linked to these conditions, respectively, implicating hormone signaling and cell growth pathways.4-6 A more recent GWAS meta-analysis of 40,024 women affected by infertility from 6 different cohorts further identified significant genetic correlations between all-cause female infertility and endometriosis and fibroids, and a correlation between anovulatory infertility and polycystic ovary syndrome (PCOS) 7. In that study, the majority of the 19 reported infertility loci were also associated with endometriosis, PCOS, or fibroids.<sup>7</sup> While the previous GWAS analyses of infertility and its related disorders in women have targeted common genetic variation, it can be expected that rare or lowfrequency recessive variants may be particularly significant causes of impaired reproduction. In fact, our previous exploration of over 40,000 coding variants across >2,000 disease phenotypes in the Finnish population cohort FinnGen, revealed a

recessive association of female infertility with low-frequency variant near *PKHDL1/EBAG9*.8 That study comprised 7,980 women affected by infertility. We now present results from an expanded recessive association analysis encompassing 22,849 women affected by infertility and 198,989 controls from the FinnGen cohort. Genetic drift and historical bottlenecks have shaped the Finnish population structure leading to an enrichment of genetic variants in the 0.5-5% allele frequency range in the current population.9 Thus, we expect the FinnGen cohort to be highly potent and well-suited for the successful identification of such mutations impacting reproduction.

### SUBJECTS AND METHODS

### Study cohort and data

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

We studied female infertility in the large Finnish research project FinnGen<sup>9</sup> (https://www.finngen.fi/en) launched in 2017. FinnGen is a public-private research project, combining genome and digital healthcare data on over 500,000 Finns. The nationwide research project aims to provide novel medically and therapeutically relevant insight into human diseases. FinnGen is a pre-competitive partnership of Finnish biobanks and their background organizations (universities and university hospitals) and international pharmaceutical industry partners and Finnish biobank ΑII cooperative (FINBB). FinnGen partners are listed here: https://www.finngen.fi/en/partners. This study is based on FinnGen data release 12 including 520,210 participants of which 293,373 (56,39 %) are females.

## Definition of female infertility

The clinical disease endpoint 'female infertility' was constructed based on the register codes using the Finnish version of the International Classification of Diseases, 10th revision (ICD-10) diagnosis codes and harmonizing them with definitions from ICD-8 and ICD-9 as follow: at least one record of female infertility diagnosis (N97\* or N98\* [ICD-10], or 628\* [ICD8 and 9]), or at least one record of purchased medication used for infertility treatments (ATC codes G03GA\* or G03GB\*) or a record of a procedure used for treatment of infertility (e.g. insemination), (NOMESCO codes: TLW00, TLW10, TLW11, TLW12, TLW14 or TLW20). Women with an infertility record including only ICD10 code N97.4 ("Female infertility associated with male factors") were excluded from the analyses. As

controls, we used women who have given birth based on data from the Medical Birth Register and the Finnish Population Register. Using these criteria, we identified 22,849 women affected by infertility and 198,989 controls.

**Table 1:** Basic characteristics of the study cohort.

	All	Cases	Controls
N (%)	221,838 [100]	22,849 [10.29]	198,989 [89.70]
Age (mean [SD]) <sup>a</sup>	61.40 [16.33]	51.09 [12.91]	62.59 [16.26]
BMI (mean [SD]) <sup>b</sup>	27.50 [5.72]	27.21 [5.96]	27.53 [5.69]
Given birth (N [%])	216,469 [97.57]	17,480 [76.50]	198,989 [100]
Age at first birth (mean [SD]) c	26.20 [5.11]	30.22 [5.77]	25.84 [4.89]
N offspring (mean [SD])	2.22 [1.22]	1.50 [1.19]	2.30 [1.19]
Endometriosis (N [%])	16,618 [7.49]	4,607 [20.16]	12,011 [6.03]
PCOS (N [%])	1,691 [0.76]	1,011 [4.42]	590 [0.29]
Leiomyoma of uterus (N [%])	35 199 [15.86]	3 346 [14.64]	31 853 [16.01]

<sup>&</sup>lt;sup>a</sup> Age at end of follow-up or death

The basic clinical characteristics of cases and controls are presented in **Table 1**. Given that the Drug Reimbursement Register contains data starting from 1995, women who have received in vitro fertilization (IVF) therapy prior to this date cannot be identified as cases unless they have received a record of infertility in the Hospital Discharge Register (HILMO). In addition, given that our resolution to distinguish

<sup>&</sup>lt;sup>b</sup> BMI information available only for 150,636 [67.90 %] women (15,453 [67.63 %] cases and 135 183 [67.93 %] controls

<sup>&</sup>lt;sup>c</sup> Information available only for women who have given birth at least once (n = 216,469, 17,489 cases and 198,989 controls).

between cases and controls is much higher for women suffering from reduced fertility starting from the mid-1990's, the FinnGen women identified as cases are younger than the controls (difference of the mean = 11.99 years, p <  $1\times$   $10^{-324}$ ; **Supplementary Figure 1**). In the analyses, this age difference has been considered by using birth year as a covariate in the GWAS analyses, and when calculating the disease prevalence. In the analyses of disease enrichment, both cases and controls have been matched by birth year.

5,701 (24.95 %) of cases were secondary infertility cases, i.e., they received the infertility diagnosis after having at least one child. On average, the cases with infertility who have at least one child were on average 4.37 years older than controls when giving birth for the first time (p <  $1 \times 10^{-324}$ ; **Supplementary Figure 2**)

## Genotyping and imputation

FinnGen samples were genotyped with multiple Illumina and Affymetrix arrays (Thermo Fisher Scientific, Santa Clara, CA, USA). Genotype calls were made with GenCall and zCall algorithms for Illumina and AxiomGT1 algorithm for Affymetrix chip genotyping data batch-wise. Genotyping data produced with previous chip platforms were lifted over to build version 38 (GRCh38/hg38) following the protocol described here: dx.doi.org/10.17504/protocols.io.nqtddwn. Samples with sex discrepancies, high genotype missingness (>\Bigci2%), excess heterozygosity in common variants (allele frequency > 0.05) (±3SD) per batch, and non-Finnish ancestry were removed. Variants with high missingness (>\Bigci2%), deviation from Hardy–Weinberg equilibrium (P\Bigci><\Bigci1x10^-6) and low minor allele count (MAC\Bigci><\Bigci3) were removed.

Pre-phasing of genotyped data was performed with Eagle 2.3.5 (https://data.broadinstitute.org/alkesgroup/Eagle/) with the default parameters, except the number of conditioning haplotypes was set to 20,000. Imputation of the genotypes was carried out by using the population-specific Sequencing Initiative Suomi (SISu) v4.2 imputation reference panel with Beagle 4.1 (version 08Jun17.d8b. https://faculty.washington.edu/browning/beagle/b4\_1.html) as described in the following protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. SISu v4.2 imputation reference panel was developed using the high-coverage (25-30x) whole-genome sequencing data generated at the Broad Institute of MIT and Harvard and at the McDonnell Genome Institute at Washington University, USA; and jointly processed at the Broad Institute. Variant callset was produced with Genomic Analysis Toolkit (GATK) HaplotypeCaller algorithm by following GATK best practices for variant calling. Genotype-, sample- and variant-wise quality control was applied in an iterative manner by using the Hail framework v0.2. The resulting high-quality WGS data for 3,775 individuals were phased with Eagle 2.3.5 as described above. As a post-imputation quality control, variants with INFO score < 0.7 were excluded.

### Genome-wide association study

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

A total of 221,838 (22,849 cases and 198,989 controls) female samples from FinnGen Data Freeze 12 were analyzed using REGENIE<sup>10</sup>. All models were adjusted for age at the end of follow-up or death, birth year, genotyping batch, and first ten principal components (PC). Both additive and recessive models were performed, using imputed genotypes (n variants = 21,296,962). Recessive analyses were performed for variants with at least 2 homozygous carriers for the minor allele (n

variants = 15,421,131). All variants reaching genome-wide significance p-value threshold of  $5\times10^{-8}$  were considered genome-wide significant (GWS). All GWS regions were fine-mapped using SUSIE<sup>11</sup>, and independent genome-wide significant loci were determined as 'good quality' credible sets from those analyses.

To investigate the effect of advanced maternal age on reduced fertility, we also performed age-stratified GWAS. Based on the maternal age corresponding to the first record of female infertility, we divided our cases into 'early-onset' ('infertility diagnosis before age of 30', n = 9,185) and 'late-onset' ('infertility diagnosis after age of 30', n = 13,664) cases (**Supplementary Figure 3**). The age-stratified analyses were performed using both the additive and the recessive GWAS models, similarly as for the 'all cases' scenario described above, using the same set of controls.

#### Genetic correlations and disease enrichment

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

To explore the connection of female infertility with underlying disorders of female reproductive traits, we calculated both 1) genetic correlations and 2) case enrichments with our female infertility endpoints across 4 disease endpoints created and analyzed in FinnGen: 'Endometriosis', 'Endometriosis ESRM stage 3 or 4', 'Leiomyoma of uterus' and 'PCOS'. A complete list of endpoints analysed in definitions FinnGen, and their is available at https://www.finngen.fi/en/researchers/clinical-endpoints. We also calculated heritability estimates for both female infertility endpoints, as well as for all the four underlying disorders of female reproductive traits listed above. Summary statistics from the additive GWAS for female infertility endpoints were used to calculate genetic correlations. The genetic correlations and heritability estimates were calculated using the LDSC software. 12,13

The prevalence in our female infertility cases and controls separately was calculated for the four underlying disorders of female reproductive traits, and its enrichment to cases vs. controls was calculated. P- values for the enrichments were calculated using Fisher's exact test<sup>14</sup>. In these analyses, controls were matched with cases for their birth year, since the birth year distribution of the controls and cases were significantly different.

### RESULTS

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179


180

**GWAS** results

To elucidate the genetic predisposition to female infertility, we performed GWAS analyses on 22,849 women affected by from infertility and 198,989 women who had given birth without a history of infertility or infertility treatment. Both a recessive and a traditional additive model were used for the analyses. The recessive GWAS pinpointed two genome-wide significant loci: one nearby PKHD1L1, and another at TBPL2. The TBPL2 locus has not been previously associated with female infertility or any disorder associated with infertility in GWAS. In contrast, PKHD1L1 has previously been implicated in two GWAS analyses of female infertility- we have reported a recessive association between PKHD1L1 and female infertility<sup>8</sup>, while Venkatesh and coworkers later reported a genome-wide significant association between the locus and female infertility using an additive model<sup>7</sup>. We next ran the additive GWAS analysis in our cohort of cases and controls and identified genome-wide significant association at four distinct loci on chromosomes 1, 4, 6, and 8 near genes WNT4, SULT1B1, ESR1, and PKHD1L1, respectively. Statistical fine-mapping further identified a fifth independent significant association signal on ESR1 locus (Figure 1). All these loci have previously been associated either with female infertility or with pre-existing conditions that increase the risk of female infertility, such as endometriosis, uterine fibroids, and PCOS (Table 2). Locuszoom plots for all significant GWS regions from both scans are available in

Supplementary Figure 4 (loci identified by the additive model) and Supplementary

Figure 5 (loci identified by the recessive model).



**Figure 1:** Manhattan plots for female infertility. Additive results are grey and recessive are blue dots. Genome-wide significant loci ( $\pm$  500 kB) have been highlighted with green and labeled with the nearest gene of the lead variant.

Given that the *PKHD1L1* locus yielded genome-wide significant association in both the recessive and the additive analyses, we analyzed the mode of inheritance for all identified association signals in more detail. For this purpose, we selected the lead variant (i.e. variant with the smallest p-value) at all significant loci, and plotted the proportion of affected cases in each genotype group (**Supplementary Figure 6** and **Supplementary Figure 7**). This data confirms that both the *PKHD1L1* and *TBPL2* loci exhibit a recessive mode of action, i.e. the proportion of cases with infertility is significantly elevated only among homozygous carriers of the effect allele. In contrast, at the remaining loci, the percentage of affected cases increases across the three genotype groups consistent with an additive mode of action.

**Table 2:** Independent GWAS hits and their representative variants identified by either additive or recessive model. The lead variant from the recessive and the additive models at the shared locus (PKHD1L1) are within the same credible set (LD = 1).

SNPID (rsid)	Most severe consequence	Nearest gene	OR [95% CI]	P-value	Maf	Fin enrichment <sup>a</sup>	Known associations <sup>c</sup>
			Recessive				
chr8_109459837_G_C (rs17368310) <sup>b</sup>	splice donor variant	PKHD1L1	2.34 [1.98-2.78]	1.47×10 <sup>-22</sup>	0.07	1.42	Female infertility
chr14_55424219_T_A (rs144313315)	stop gained	TBPL2	650.1 [190.7-2216.1]	4.11×10 <sup>-25</sup>	0.01	43.04	-
-	Additive						
chr1_22139327_T_C (rs61768001)	intron variant	WNT4	1.10 [1.07-1.13]	4.4×10 <sup>-12</sup>	0.16	0.99	Endometriosis, fibroids
chr4_69718365_T_G (rs13138435)	downstream gene variant	SULT1B1	0.93 0.91-0.95]	4.57×10 <sup>-10</sup>	0.31	0.8	Uterine leiomyomata and fibroids
chr6_151230382_G_T (rs35977392)	upstream gene variant	ESR1	0.93 0.91-0.95]	3.97×10 <sup>-11</sup>	0.35	0.88	Endometriosis
chr8_109459837_G_C (rs17368310)	splice donor variant	PKHD1L1	1.19 [1.14-1.23]	3.79×10 <sup>-18</sup>	0.07	1.42	Female infertility

<sup>&</sup>lt;sup>a</sup> Compared to Non-Finnish Europeas in gnomAD v3<sup>15</sup>

All three loci identified to have an additive effect showed evidence for pleiotropy, i.e. assessment of the infertility-associated loci by PheWas of 2,460 endpoints in FinnGen indicated association with two or more other diseases of the female

<sup>&</sup>lt;sup>b</sup> Representative variant was changed to coding variant from lead variant chr8\_109515401\_CAAT\_C (rs58870933),  $r^2 = 1$ .

<sup>&</sup>lt;sup>C</sup> Known associations for genes have been defined from NHGRI-EBI GWAS Catalog<sup>16</sup> and previous publications for female infertility and underlying disorders.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230


231

232

233

reproductive tract. In contrast, the two recessive loci (near TBPL2 and PKHD1L1) were specifically associated only with infertility (**Table 2**). TBPL2 locus The strongest association was observed in the recessive analysis at the TBPL2 locus, with an OR of 650.1 (p =  $4.11 \times 10^{-25}$ ). The lead variant in this locus. rs144313315 (chr14:55424219\_T/A), is a rare stop-gained mutation (p.Arg331Ter, MAF 1.1% in Finland) which is highly enriched to Finland (43 times compared to non-Finnish Europeans). The variant appears rather evenly distributed across Finland, with an allele frequency range of 0.84-2.38 % (Supplementary Figure 8). Although infertility is a condition causing considerable stress to patients, most affected women will successfully conceive a child. To assess the prognosis for women carrying two copies of the TPBL2 mutation, we analyzed the number of offspring in the entire FinnGen cohort across the TBPL2 genotype groups. The average number of offspring among all FinnGen women with and without a history of infertility is 1.50 [SD = 1.19] vs. 1.77 [SD = 1.43], respectively. However, the average number of offspring was significantly reduced among homozygous female carriers of the p.Arg331Ter mutation. PheWAS analysis revealed a genome-wide significant recessive association between the mutation and the number of offspring ( $\beta = -1.28$ SD, p =  $4.25 \times 10^{-15}$ ) with homozygous carriers having an average of only 0.16 [SD=0.58] offspring. According to the registry data, only four homozygous women for the TBPL2 mutation had given birth, and none of them had conceived without infertility treatment (Figure 2: Supplementary Table 1). No such effect was

observed at the *PKHD1L1* locus, where the number of offspring was only slightly reduced among homozygous carriers of the minor allele (**Supplementary Figure 9**).



**Figure 2:** Average number of offspring for genotype groups for rs14413315 (*TBPL2* stopgained variant) separately for females and males who have reached age 45. The dashed line represents the overall average number of offspring in FinnGen among women who have reached age 45 (=1.96).

These data indicate that the p.Arg331Ter mutation in *TPBL2* is associated with a rather severe form of infertility. These results are supported by previously published studies in mice, which reported that female mice lacking this gene are infertile female mice due to anovulation.

### Age-stratified analysis

Female fertility gradually decreases with age, starting to decline more rapidly in women in their early thirties. To assess whether genetic susceptibility varies with age, we conducted age-stratified analyses. We analyzed women diagnosed with or treated for infertility below the age of 30 (early-onset) separately from those diagnosed or treated at age 30 or above (late-onset). These age-stratified analyses identified three additional genome-wide significant loci associated with infertility: two with early-onset disease near *CHEK2* and the major histocompatibility complex (MHC) region on chromosome 9, and one with late-onset disease, with the lead SNP located in an intron of the IncRNA gene ENSG00000284418 (Supplementary Figure 10)

The strongest association signal exclusively associated with early-onset infertility was a frameshift mutation, c.1100delC (rs555607708), in *CHEK2*, which previously has been shown to confer increased risk for breast and ovarian cancer. The mutation is additionally associated with leiomyoma, thyroid cancer, and myeloproliferative disorders in FinnGen. A recent study including women from FinnGen and the Estonian biobank further reported that the mutation is associated with an increased risk for PCOS (OR = 13.46 [5.68-31.89], p =  $1.68\times10^{-9}$ )<sup>17</sup>

The other association signal exclusively associated with early-onset infertility was within the major histocompatibility complex (MHC) region. To pinpoint the exact location of the signal, we imputed the classical HLA alleles as well as *MICA* and *MICB*<sup>18</sup> and tested these alleles for association with our female infertility endpoints. None of the tested variants showed significant association for any of the infertility

endpoint tested. The complete association results of these additional association tests across the MHC region are presented in **Supplementary Table 2**.

### Genetic correlations and case enrichments among cases

Given that three of the significantly associated loci detected by the primary GWAS analyses showed pleiotropic association with female reproductive system disorders, such as PCOS, endometriosis, and leiomyoma of the uterus, we next examined their genetic overlap with infertility on a genomic scale. The strongest genetic correlation (rg) was observed between infertility and endometriosis (rg = 0.46, p =  $2.69 \times 10^{-15}$ ), with similar correlation estimates with endometriosis found among both early-onset and late-onset cases (**Supplementary Figure 11**). In contrast, although there was a significant enrichment of PCOS among women affected by infertility (**Table 3**), the genetic correlation between the two diseases was only 0.22 (p = 0.014). Interestingly, both the genetic correlation and case enrichment with PCOS increased among early-onset cases. Heritability estimates for all analyzed female infertility-related endpoints are presented in **Supplementary Figure 12**.

# **Table 3:** Genetic correlations with female infertility (rg) and enrichment of female infertility cases (Enrichment) among four underlying disorders for female reproduction.

Phenotype	N cases	rg [95% CI]	P-value (rg)	Enrichment	P-value (Enr)
Endometriosis	20 190	0.46 [0.35-0.58]	2.69×10 <sup>-15</sup>	3.83	< 1× 10 <sup>-324</sup>
Endometriosis ASRM stages 3,4	10 127	0.48 [0.35-0.61]	1.76×10 <sup>-13</sup>	5.53	< 1× 10 <sup>-324</sup>
Leiomyoma of uterus	42 107	0.30 [0.19-0.41]	8.78×10 <sup>-08</sup>	1.44	1.01×10 <sup>-73</sup>
Polycystic ovarian syndrome (PCOS)	2 214	0.22 [0.04-0.39]	0.014	9.27	< 1× 10 <sup>-324</sup>

### DISCUSSION

Our GWAS analyses, encompassing more than 20,000 Finnish women affected by infertility and 198,000 controls, showcase a diverse landscape of associated loci. The analyses reveal that a portion of unexplained female infertility may be attributed to high-impact recessively acting disruptive mutations present at >1% frequency in the population. Specifically, our analyses point to a mutation in the Tata-box binding protein-like 2 gene (*TBPL2*), which encodes a transcription factor protein crucial for transcription initiation during oocyte growth. Based on our findings, this mutation is a significant contributor to female infertility in Finland. <sup>19</sup> The mutation introduces a premature stop codon (p.Arg331Ter) in the terminal DNA-binding part of the protein, and can hence be expected to significantly impair the transcription of the downstream targets. In our follow-up analyses, the *TBPL2* mutation was associated only with infertility and no other diseases. The variant's association with a smaller number of offspring suggests that the mutation is associated with severe infertility Prior data have indeed shown that the absence of *TBPL2* leads to oocytes failing to develop and renders female mice sterile. <sup>20</sup>

According to data from GnomAD (v3.1.2), loss-of-function mutations in *TBPL2* are rare, with the stop-gained mutation associated with infertility in this study being an exception. Apart from our findings, there are only scattered reports of coding mutations in *TBPL2* detected in women with infertility. Three reports describe homozygous and compound heterozygous stop-gained mutations (c.788+3A>G, p.Arg233Ter and c.802C>T, p.Arg268Ter) in women with infertility from four unrelated Chinese families.<sup>21,22</sup> In a fourth report, a homozygous missense mutation was linked to infertility, oocyte maturation arrest, and degradation in two sisters from

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

a consanguineous family.<sup>23</sup> Notably, all published cases have exhibited treatmentresistant primary infertility. In our study, most homozygous mutation carriers had not given birth. However, based on data from the Medical Birth Register, two out of 41 carriers had given birth to one child, whereas two carriers had given birth to more than one child. All four women had undergone IVF therapy, although more detailed information on the potential use of donor oocytes is not available. Over the past few decades, there has been a considerable shift in childbearing demographics in developed countries, characterized by more women choosing to delay childbearing. 24,25 Since a woman's age is one of the key factors influencing fertility, this trend has resulted in a higher average age at which women first experience infertility. This pattern is also evident in FinnGen, where we observe steadily increasing ages at first birth among women born between the 1950s and the 1980s ( **Supplementary Figure 13**). Interestingly, previous research indicates that the causes of infertility may differ between older and younger women, with those over 35 years of age being nearly twice as likely to experience unexplained infertility compared to younger women.<sup>26</sup> In support of specific age-dependent mechanisms, our GWAS analyses suggest that some associated loci indeed exert their effect in an age-dependent manner. Some loci, such as TBPL2, are uniformly associated with infertility in both early and lateonset cases, but we identified two loci uniquely associated with infertility only among women diagnosed before age 30, and one locus associated with late-onset disease. One of the loci associated with early-onset infertility is a frameshift alteration (c.1100delC) in the tumor suppressor gene CHEK2, associated with a 32% lifetime

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

risk for breast cancer.<sup>27</sup> Finding association with early-onset infertility likely reflects a link with PCOS, as the c.1100delC mutation is significantly associated with PCOS in FinnGen <sup>16</sup>, and the proportion of PCOS cases is increased among women with early-onset infertility compared to all infertility cases (0.077 vs. 0.046, respectively). The second locus associated with the early-onset infertility was the major histocompatibility complex (MHC) region on chromosome 6. The data indicate that the association is rather sharply defined to a region between 30018523 and 33018523 bp on chromosome 6, and fine-mapping analyses suggest that the signal is not associated with the classical MHC effect. The classical MHC genes encode proteins involved in antigen presentation to T cells, whereas a key function for nonclassical MHC I molecules is to mediate inhibitory or activating stimuli in natural killer (NK) cells. Given that the survival of the embryo in the uterus depends on the maintenance of immune tolerance at the maternal-fetal interface, and that the pregnant uterus is predominantly populated with NK cells, one may speculate that the association findings tag an underlying mechanism that might be related to local immune tolerance.<sup>28</sup> Further functional studies are nonetheless warranted to explore and verify such an effect. Taken together, our data point towards a unique landscape of genetic factors associated with female infertility. The results specifically highlight the significant role of recessive low-frequency variants, with the stop-gained mutation in TBPL2 exhibiting an impact comparable to highly penetrant monogenic mutations.

### **REFERENCES**

- Organization, W. H. & others. Infertility Prevalence Estimates: 1990–2021.
   2023.
- Carson, S. A. & Kallen, A. N. Diagnosis and Management of Infertility: A Review. *JAMA - Journal of the American Medical Association* vol. 326 Preprint at https://doi.org/10.1001/jama.2021.4788 (2021).
- 3. Sadeghi, M. R. Unexplained infertility, the controversial matter in management of infertile couples. *Journal of Reproduction and Infertility* vol. 16 Preprint at (2015).
- Day, F. et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria.
   PLoS Genet 14, (2018).
- 5. Rahmioglu, N. *et al.* The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. *Nat Genet* **55**, (2023).
- 6. Gallagher, C. S. *et al.* Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. *Nat Commun* **10**, (2019).
- 7. Venkatesh, S. S. *et al.* Genome-wide analyses identify 21 infertility loci and over 400 reproductive hormone loci across the allele frequency spectrum. *medRxiv* 2023–2024 (2024).
- 8. Heyne, H. O. *et al.* Mono- and biallelic variant effects on disease at biobank scale. *Nature* **613**, (2023).
- 9. Kurki, M. I. *et al.* Author Correction: FinnGen provides genetic insights from a well-phenotyped isolated population (Nature, (2023), 613, 7944, (508-518),

- 10.1038/s41586-022-05473-8). *Nature* Preprint at https://doi.org/10.1038/s41586-023-05837-8 (2023).
- 10. Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* **53**, (2021).
- Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach
  to variable selection in regression, with application to genetic fine mapping. *J R*Stat Soc Series B Stat Methodol 82, (2020).
- 12. Bulik-Sullivan, B. *et al.* LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, (2015).
- 13. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet* **47**, (2015).
- 14. Fisher, R. A. On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P. *Journal of the Royal Statistical Society* **85**, (1922).
- 15. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, (2020).
- 16. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, (2019).
- 17. Tyrmi, J. S. *et al.* Leveraging Northern European population history: Novel low-frequency variants for polycystic ovary syndrome. *Human Reproduction* **37**, (2022).
- Tammi, S. et al. Accurate multi-population imputation of MICA, MICB, HLA-E,
   HLA-F and HLA-G alleles from genome SNP data. bioRxiv 2023.12.05.570226
   (2023) doi:10.1101/2023.12.05.570226.

- 19. Yu, C. *et al.* TBPL2/TFIIA complex establishes the maternal transcriptome through oocyte-specific promoter usage. *Nat Commun* **11**, (2020).
- 20. Gazdag, E. *et al.* TBP2 is essential for germ cell development by regulating transcription and chromatin condensation in the oocyte. *Genes Dev* **23**, (2009).
- Du, T. et al. Compound heterozygous mutations in TBPL2 were identified in an infertile woman with impaired ovarian folliculogenesis. J Assist Reprod Genet 40, (2023).
- 22. Tora, L. & Vincent, S. D. What defines the maternal transcriptome? Biochemical Society Transactions vol. 49 Preprint at https://doi.org/10.1042/BST20201125 (2021).
- 23. Wang, Y. *et al.* A homozygous missense mutation in TBPL2 is associated with oocyte maturation arrest and degeneration. *Clin Genet* **100**, (2021).
- 24. Hochler, H. *et al.* The Impact of Advanced Maternal Age on Pregnancy Outcomes: A Retrospective Multicenter Study. *J Clin Med* **12**, (2023).
- 25. Heffner, L. J. Advanced Maternal Age How Old Is Too Old? *New England Journal of Medicine* **351**, (2004).
- 26. Maheshwari, A., Hamilton, M. & Bhattacharya, S. Effect of female age on the diagnostic categories of infertility. *Human Reproduction* **23**, (2008).
- 27. Mars, N. et al. The role of polygenic risk and susceptibility genes in breast cancer over the course of life. *Nat Commun* **11**, (2020).
- Sharma, S. Natural killer cells and regulatory T cells in early pregnancy loss.
   International Journal of Developmental Biology vol. 58 Preprint at https://doi.org/10.1387/ijdb.140109ss (2014).

# List of Figures

### List of Tables

### **Ethics statement**

Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/283/6.02.00/2019, THL/2222/6.02.00/2018, THL/1721/5.05.00/2019 THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA KELA 2/522/2020, 16/522/2020), **Findata** permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics Finland (permit TK/143/07.03.00/2020 numbers: TK-53-1041-17 (earlier TK-53-90-20) and

TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 11 include: THL Biobank BB2017 55, BB2017 111, BB2018 19, BB\_2018\_34, BB\_2018\_67, BB2018\_71, BB2019\_7, BB2019\_8, BB2019\_26, BB2020\_1, BB2021\_65, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, HUS/430/2021 §28, §29, HUS/150/2022 §12, §13, §14, §15, §16, §17, §18, §23, §58, §59, HUS/128/2023 §18, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and amendments BB\_2021-0140, BB\_2021-0156 (August 26 2021, Feb 2 2022), BB\_2021-0169, BB\_2021-0179, BB\_2021-0161, AB20-5926 and amendment #1 (April 23 2020) and it's modifications (Sep 22 2021), BB 2022-0262, BB 2022-0256, Biobank Borealis of Northern Finland\_2017\_1013, 2021\_5010, 2021 5010 2021 5018, 2021 5018 Amendment, 2021 5015, 2021 5015 Amendment, 2021 5015 Amendment 2, 2021 5023, 2021 5023 Amendment, 2021 5023 Amendment 2, 2021 5017, 2021 5017 Amendment, 2022 6001, Amendment, 2022 6001 Amendment, 2022\_6006 Amendment, 2022\_6006 2022\_6006 Amendment\_2, BB22-0067, 2022\_0262, 2022\_0262 Amendment, Biobank of Eastern Finland 1186/2018 and amendment 22\\$/2020, 53\\$/2021, 13\\$/2022, 14\\$/2022, 15\\$/2022, 27\\$/2022, 28\\$/2022, 29\\$/2022, 33\\$/2022, 35\\$/2022, 36\\$/2022, 37\\$/2022, 39\\$/2022, 7\\$/2023, 32\\$/2023, 33\\$/2023, 34\\$/2023, 35\\$/2023, 36§/2023, 37§/2023, 38§/2023, 39§/2023, 40§/2023, 41§/2023, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), BB2021-0140 8\\$/2021, 9\\$/2021, \\$9/2022, \\$10/2022, \\$12/2022, 13\\$/2022, \\$20/2022,

§21/2022, §22/2022, §23/2022, 28§/2022, 29§/2022, 30§/2022, 31§/2022, 32§/2022, 38§/2022, 40§/2022, 42§/2022, 1§/2023, Central Finland Biobank 1-2017, BB\_2021-0161, BB\_2021-0169, BB\_2021-0179, BB\_2021-0170, BB\_2022-0256, BB\_2022-0262, BB22-0067, Decision allowing to continue data processing until 31st Aug 2024 for projects: BB\_2021-0179, BB22-0067,BB\_2022-0262, BB\_2021-0170, BB\_2021-0164, BB\_2021-0161, and BB\_2021-0169, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020, Finnish Hematological Registry and Clinical Biobank decision 18th June 2021, Arctic biobank P0844: ARC\_2021\_1001.

# **Declaration of interests**

The authors declare no competing interests.

# Data and code availability

Individual level data: The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB. Finnish Health register data can be applied from Findata (https://findata.fi/en/data/).

Summary statistics: Summary statistics from each data release will be made publicly available after a one year embargo period and can be accessed freely from: www.finngen.fi/en/access\_results.

# Acknowledgements

We want to acknowledge the participants and investigators of the FinnGen study. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc., Novartis AG, and Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-jaopetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research\_and\_development/Finnish\_Clinical\_Biobank\_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) Biobank (https://www.oulu.fi/en/university/faculties-and-units/facultymedicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members BBMRI.fi of infrastructure (https://www.bbmri-eric.eu/nationalnodes/finland/). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

# Full list of FinnGen authors

Full Name	Affiliation	E-mail	
Aarno Palotie	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	aarno.palotie@helsinki.fi	
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@helsinki.fi	
Bridget Riley-Gills	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com	
Howard Jacob	Abbvie, Chicago, IL, United States	howard.jacob@abbvie.com	
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	dirk.paul@astrazeneca.com	
Slavé Petrovski	Astra Zeneca, Cambridge, United Kingdom	slav.petrovski@astrazeneca.com	
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com	
Sally John	Biogen, Cambridge, MA, United States	sally.john@biogen.com	
George Okafo	Boehringer Ingelheim, Ingelheim am Rhein, Germany	george.okafo@boehringer-ingelheim.com	
Robert Plenge	Bristol Myers Squibb, New York, NY, United States	robert.plenge@bms.com	
Joseph Maranville	Bristol Myers Squibb, New York, NY, United States	joseph.maranville@bms.com	
Mark McCarthy	Genentech, San Francisco, CA, United States	mccarthy.mark@gene.com	
Margaret G. Ehm	GlaxoSmithKline, Collegeville, PA, United States	meg.g.ehm@gsk.com	
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com	
Simonne Longerich	Merck, Kenilworth, NJ, United States	simonne.longerich@merck.com	
Anders Mälarstig	Pfizer, New York, NY, United States	anders.malarstig@pfizer.com	
Katherine Klinger	Translational Sciences, Sanofi R&D, Framingham, MA, USA	katherine.klinger@sanofi.com	
Clement Chatelain	Translational Sciences, Sanofi R&D, Framingham, MA, USA	clement.chatelain@sanofi.com	
Matthias Gossel	Translational Sciences, Sanofi R&D, Framingham, MA, USA	matthias.gossel@sanofi.com	
Karol Estrada	Maze Therapeutics, San Francisco, CA, United States	kestrada@mazetx.com	
Robert Graham	Maze Therapeutics, San Francisco, CA, United States	rgraham@mazetx.com	
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com	

	Novartis Institutes for BioMedical Research,	
Chris O'Donnell	Cambridge, MA, United States	chris.odonnell@novartis.com
Nicole Renaud	Novartis Institutes for BioMedical Research,  Cambridge, MA, United States	nicole.renaud@novartis.com
Tomi P. Mäkelä	HiLIFE, University of Helsinki, Finland, Finland	tomi.makela@helsinki.fi
Jaakko Kaprio	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	jaakko.kaprio@helsinki.fi
Petri Virolainen	Auria Biobank / University of Turku / Hospital  District of Southwest Finland, Turku, Finland	petri.virolainen@tyks.fi
Antti Hakanen	Auria Biobank / University of Turku / Hospital  District of Southwest Finland, Turku, Finland	antti.hakanen@tyks.fi
Terhi Kilpi	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	terhi.kilpi@thl.fi
Markus Perola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markus.perola@thl.fi
Jukka Partanen	Finnish Red Cross Blood Service / Finnish  Hematology Registry and Clinical Biobank,  Helsinki, Finland	jukka.partanen@veripalvelu.fi
Anne Pitkäranta	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	anne.pitkaranta@hus.fi
Taneli Raivio	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	taneli.raivio@hus.fi
Jani Tikkanen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	jani.tikkanen@ppshp.fi
Raisa Serpi	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	raisa.serpi@ppshp.fi
Tarja Laitinen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi
Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	veli-matti.kosma@uef.fi
Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland	jari.laukkanen@ksshp.fi
Marco Hautalahti	FINBB - Finnish biobank cooperative	marco.hautalahti@finbb.fi
Outi Tuovila	Business Finland, Helsinki, Finland	outi.tuovila@businessfinland.fi

	hhyio Chicago II United States		
Dridget Diley Cillie	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com	
Bridget Riley-Gillis A	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com	
Fedik Rahimov A	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com	
Ioanna Tachmazidou A	Astra Zeneca, Cambridge, United Kingdom	ioanna.tachmazidou@astrazeneca.com	
Chia-Yen Chen B	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com	
Heiko Runz B	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com	
Zhihao Ding	Boehringer Ingelheim, Ingelheim am Rhein,	zhihao.ding@boehringer-ingelheim.com	
	Germany	Zilinao.uing@boeiiinigei-ingemeiii.com	
	Boehringer Ingelheim, Ingelheim am Rhein,	marc_oliver.jung@boehringer-	
Marc Jung	Germany	ingelheim.com	
Hanati Tuoken	Boehringer Ingelheim, Ingelheim am Rhein,	hanati.tuoken@boehringer-ingelheim.com	
	Germany		
Shameek Biswas B	Bristol Myers Squibb, New York, NY, United States	Shameek.Biswas@bms.com	
Rion Pendergrass G	Genentech, San Francisco, CA, United States	penders2@gene.com	
Margaret G. Ehm	GlaxoSmithKline, Collegeville, PA, United States	meg.g.ehm@gsk.com	
David Pulford G	GlaxoSmithKline, Stevenage, United Kingdom	david.x.pulford@gsk.com	
Neha Raghavan M	Merck, Kenilworth, NJ, United States	neha.raghavan@merck.com	
Adriana Huertas-Vazquez M	Merck, Kenilworth, NJ, United States	adriana.huertas.vazquez@merck.com	
Jae-Hoon Sul N	Merck, Kenilworth, NJ, United States	jae.hoon.sul@merck.com	
Anders Mälarstig P	Pfizer, New York, NY, United States	anders.malarstig@pfizer.com	
Xinli Hu P	Pfizer, New York, NY, United States	xinli.hu@pfizer.com	
Åsa Hedman P	Pfizer, New York, NY, United States	asa.hedman@pfizer.com	
	Franslational Sciences, Sanofi R&D, Framingham,	katharina klingar@aanafi aam	
Katherine Klinger	MA, USA	katherine.klinger@sanofi.com	
	Maze Therapeutics, San Francisco, CA, United	raraham@mazaty.com	
Robert Graham S	States	rgraham@mazetx.com	
Manuel Rivas	Maze Therapeutics, San Francisco, CA, United	mrivas@mazetx.com	
	States	mirasemazercom	
	Janssen Research & Development, LLC, Spring	d	
Dawn Waterworth	House, PA, United States	dwaterwo@its.jnj.com	
	Novartis Institutes for BioMedical Research,		
Nicole Renaud C	Cambridge, MA, United States	nicole.renaud@novartis.com	
	Novartis Institutes for BioMedical Research,		
Ma´en Obeidat	Cambridge, MA, United States	maen.obeidat@novartis.com	
	Novartis Institutes for BioMedical Research,	ionathan chung@novertic.com	
Jonathan Chung C	Cambridge, MA, United States	jonathan.chung@novartis.com	
	Novartis Institutes for BioMedical Research,	iones zierer@nevertic.com	
Jonas Zierer	Cambridge, MA, United States	jonas.zierer@novartis.com	

	Novartis Institutes for BioMedical Research,	I
Mari Niemi	Cambridge, MA, United States	mari.niemi@novartis.com
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	samuli.ripatti@helsinki.fi
Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland	johanna.schleutker@utu.fi
Markus Perola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markus.perola@thl.fi
Mikko Arvas	Finnish Red Cross Blood Service / Finnish  Hematology Registry and Clinical Biobank,  Helsinki, Finland	mikko.arvas@veripalvelu.fi
Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	olli.carpen@helsinki.fi
Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	reetta.hinttala@oulu.fi
Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kettunen@oulu.fi
Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, Kuopio, Finland	arto.mannermaa@uef.fi
Katriina Aalto-Setälä	Faculty of Medicine and Health Technology,  Tampere University, Tampere, Finland	katriina.aalto-setala@tuni.fi
Mika Kähönen	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland	mika.kahonen@uta.fi
Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, Jyväskylä, Finland	jari.laukkanen@ksshp.fi
Johanna Mäkelä	FINBB - Finnish biobank cooperative	johanna.makela@finbb.fi
Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland	reetta.kalviainen@kuh.fi
Valtteri Julkunen	Northern Savo Hospital District, Kuopio, Finland	valtteri.julkunen@kuh.fi
Hilkka Soininen	Northern Savo Hospital District, Kuopio, Finland	hilkka.soininen@uef.fi
Anne Remes	Northern Ostrobothnia Hospital District, Oulu, Finland	anne.remes@oulu.fi
Mikko Hiltunen	University of Eastern Finland, Kuopio, Finland	mikko.hiltunen@uef.fi
India Dakala	Pirkanmaa Hospital District, Tampere, Finland	jukka.peltola@pshp.fi
Jukka Peltola	Tirkaninaa Hospitai District, Tampere, Tirilana	Januar pontona O pontpini

	Finland	
Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki,	pentti.tienari@hus.fi
	Finland	
Juha Rinne	Hospital District of Southwest Finland, Turku,	juha.rinne@tyks.fi
	Finland	Januari Carpioni
Roosa Kallionpää	Hospital District of Southwest Finland, Turku,	roosa kalliannaa @huka fi
Roosa Kalilonpaa	Finland	roosa.kallionpaa@tyks.fi
	Institute for Molecular Medicine Finland, HiLIFE,	_
Juulia Partanen	University of Helsinki, Finland	juulia.partanen@helsinki.fi
Adam Ziemann	Abbvie, Chicago, IL, United States	adam.ziemann@abbvie.com
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Susan Eaton	Biogen, Cambridge, MA, United States	susan.eaton@biogen.com
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com
Sanni Lahdenperä	Biogen, Cambridge, MA, United States	sanni.lahdenpera@biogen.com
Shameek Biswas	Bristol Myers Squibb, New York, NY, United States	shameek.biswas@bms.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Edmond Teng	Genentech, San Francisco, CA, United States	teng.edmond@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom	chun-fang.2.xu@gsk.com
David Pulford	GlaxoSmithKline, Stevenage, United Kingdom	david.x.pulford@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Laura Addis	GlaxoSmithKline, Brentford, United Kingdom	laura.x.addis@gsk.com
John Eicher	GlaxoSmithKline, Brentford, United Kingdom	john.d.eicher@gsk.com
Oin ania C.Li	Janssen Research & Development, LLC, Titusville,	Olio@italini
Qingqin S Li	NJ 08560, United States	QLi2@its.jnj.com
Karen He	Janssen Research & Development, LLC, Spring	khe2@its.jnj.com
Kalenine	House, PA, United States	Kilez @its.jiij.com
Floring What was a	Janssen Research & Development, LLC, Spring	-1.h @i4 ii
Ekaterina Khramtsova	House, PA, United States	ekhramts@its.jnj.com
Neha Raghavan	Merck, Kenilworth, NJ, United States	neha.raghavan@merck.com
Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki,	martti.farkkila@hus.fi
ινιαι (ΙΙΙ ΑΙΝΝΙΙΑ	Finland	maru.larknia@Hus.il
	Hospital District of Helsinki and Uusimaa, Helsinki,	
Jukka Koskela	Finland	jukka.koskela@helsinki.fi
Compac Bildersins	Hospital District of Helsinki and Uusimaa, Helsinki,	compace pikkorsines @bus #
Sampsa Pikkarainen	Finland	sampsa.pikkarainen@hus.fi
Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland	airi.jussila@pshp.fi
Katri Kaukinen	Pirkanmaa Hospital District, Tampere, Finland	katri.kaukinen@tuni.fi

Timo Blomster	Northern Ostrobothnia Hospital District, Oulu, Finland	timo.blomster@ppshp.fi
Mikko Kiviniemi	Northern Savo Hospital District, Kuopio, Finland	mikko.kiviniemi@kuh.fi
Markku Voutilainen	Hospital District of Southwest Finland, Turku, Finland	markku.voutilainen@tyks.fi
Mark Daly	Institute for Molecular Medicine, Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@helsinki.fi
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Tim Lu	Genentech, San Francisco, CA, United States	lut8@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom	linda.c.mccarthy@gsk.com
Amy Hart	Janssen Research & Development, LLC, Spring House, PA, United States	ahart13@its.jnj.com
Meijian Guan	Janssen Research & Development, LLC, Spring House, PA, United States	mguan4@its.jnj.com
Jason Miller	Merck, Kenilworth, NJ, United States	jason.miller4@merck.com
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.miller@pfizer.com
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com
Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	kari.eklund@hus.fi
Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland	ajpalo@utu.fi
Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland	pia.isomaki@pshp.fi
Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland	laura.pirila@fimnet.fi,laura.pirila@tyks.fi
Oili Kaipiainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland	oili.kaipiainen-seppanen@kuh.fi
Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland	johanna.huhtakangas@kuh.fi
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com

Apinya Lertratanakul	Abbvie, Chicago, IL, United States	apinya.lertratanakul@abbvie.com
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Coralie Viollet	AstraZeneca, Cambridge, United Kingdom	coralie.viollet@astrazeneca.com
Marla Hochfeld	Bristol Myers Squibb, New York, NY, United States	mhochfeld@celgene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom	jorge.x.esparza-gordillo@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com
Fabiana Farias	Merck, Kenilworth, NJ, United States	fabiana.farias@merck.com
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com
Nan Bing	Pfizer, New York, NY, United States	nan.bing@pfizer.com
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi
Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland	margit.pelkonen@kuh.fi
Paula Kauppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	paula.kauppi@hus.fi
Hannu Kankaanranta	University of Gothenburg, Gothenburg, Sweden/ Seinäjoki Central Hospital, Seinäjoki, Finland/ Tampere University, Tampere, Finland	hannu.kankaanranta@tuni.fi
Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland	terttu.harju@oulu.fi
Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland	rilahes@utu.fi
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Coralie Viollet	AstraZeneca, Cambridge, United Kingdom	coralie.viollet@astrazeneca.com
Susan Eaton	Biogen, Cambridge, MA, United States	susan.eaton@biogen.com
Hubert Chen	Genentech, San Francisco, CA, United States	chenh37@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom	joanna.c.betts@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom	rajashree.x.mishra@gsk.com
Majd Mouded	Novartis, Basel, Switzerland	majd.mouded@novartis.com
Debby Ngo	Novartis, Basel, Switzerland	debby.ngo@novartis.com
Teemu Niiranen	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	teemu.niiranen@thl.fi

		T
Felix Vaura	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	fechva@utu.fi
Veikko Salomaa	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	veikko.salomaa@thl.fi
Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland	kaj.metsarinne@tyks.fi
Jenni Aittokallio	Hospital District of Southwest Finland, Turku, Finland	jemato@utu.fi
Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland	mika.kahonen@uta.fi
Jussi Hernesniemi	Pirkanmaa Hospital District, Tampere, Finland	jussi.hernesniemi@tuni.fi
Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	daniel.gordin@hus.fi
Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	juha.sinisalo@hus.fi
Marja-Riitta Taskinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	marja-riitta.taskinen@helsinki.fi
Tiinamaija Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tiinamaija.tuomi@hus.fi
Timo Hiltunen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	timo.hiltunen@hus.fi
Jari Laukkanen	Central Finland Health Care District, Jyväskylä, Finland	jari.laukkanen@ksshp.fi
Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston, MA, USA	aelliott@broadinstitute.org
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi
Sanni Ruotsalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	sanni.ruotsalainen@helsinki.fi
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	dirk.paul@astrazeneca.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom	audrey.y.chu@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Dermot Reilly	Janssen Research & Development, LLC, Boston, MA, United States	dreill11@its.jnj.com
Mike Mendelson	Novartis, Boston, MA, United States	mike.mendelson@novartis.com
-		+

Jaakko Parkkinen	Pfizer, New York, NY, United States	jaakko.parkkinen@pfizer.com
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.miller@pfizer.com
Tuomo Meretoja	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuomo.meretoja@hus.fi
Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	heikki.joensuu@hus.fi
Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	olli.carpen@helsinki.fi
Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	johanna.mattson@hus.fi
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi
Annika Auranen	Pirkanmaa Hospital District , Tampere, Finland	anaura@utu.fi
Peeter Karihtala	Northern Ostrobothnia Hospital District, Oulu, Finland	peeter.karihtala@oulu.fi
Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland	paivi.auvinen@kuh.fi
Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland	klaus.elenius@utu.fi
Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland	johanna.schleutker@utu.fi
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	esa.pitkanen@helsinki.fi
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@helsinki.fi
Relja Popovic	Abbvie, Chicago, IL, United States	relja.popovic@abbvie.com
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Margarete Fabre	AstraZeneca, Cambridge, United Kingdom	margarete.fabre@astrazeneca.com
Jennifer Schutzman	Genentech, San Francisco, CA, United States	schutzman.jennifer@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom	diptee.a.kulkarni@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Alessandro Porello	Janssen Research & Development, LLC, Spring	APorrell@ITS.JNJ.com

Andrey Loboda  Merck, Kenilworth, NJ, United States  Andrey_loboda@merck.com  Pfizer, New York, NY, United States  Pfizer, New York, NY, United States  Stefan.McDonough@pfizer.com  Stefan McDonough  Pfizer, New York, NY, United States  Stefan.McDonough@pfizer.com  Sauli Vuoti  Janssen-Cilag Oy, Espoo, Finland  Northern Savo Hospital District, Kuopio, Finland;  Department of Molecular Genetics, University of  Lodz, Lodz, Poland  Helsinki University Hospital and University of  Helsinki, Helsinki, Finland; Eye Genetics Group,  Folkhälsan Research Center, Helsinki, Finland  Terhi Ollila  Hospital District of Helsinki and Uusimaa, Helsinki,  Finland  Pirkanmaa Hospital District, Tampere, Finland  hannu.uusitalo@tuni.fi	
Stefan McDonough Pfizer, New York, NY, United States Stefan.McDonough@pfizer.com Sauli Vuoti Janssen-Cilag Oy, Espoo, Finland Northern Savo Hospital District, Kuopio, Finland; Department of Molecular Genetics, University of Lodz, Lodz, Poland Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland Terhi Ollila Hospital District of Helsinki and Uusimaa, Helsinki, Finland terhi.ollila@hus.fi	
Sauli Vuoti  Janssen-Cilag Oy, Espoo, Finland  Northern Savo Hospital District, Kuopio, Finland;  Kai Kaarniranta  Department of Molecular Genetics, University of Lodz, Lodz, Poland  Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland  Hospital District of Helsinki and Uusimaa, Helsinki, Finland  terhi.ollila@hus.fi	
Northern Savo Hospital District, Kuopio, Finland; Department of Molecular Genetics, University of Lodz, Lodz, Poland  Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland  Terhi Ollila  Northern Savo Hospital District, Kuopio, Finland; kai.kaarniranta@uef.fi  kai.kaarniranta@uef.fi  joni.turunen@helsinki.fi  terhi.ollila@hus.fi	
Kai Kaarniranta  Department of Molecular Genetics, University of Lodz, Lodz, Poland  Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland  Terhi Ollila  Hospital District of Helsinki and Uusimaa, Helsinki, Finland  terhi.ollila@hus.fi	
Lodz, Lodz, Poland  Helsinki University Hospital and University of  Joni A Turunen  Helsinki, Helsinki, Finland; Eye Genetics Group, joni.turunen@helsinki.fi  Folkhälsan Research Center, Helsinki, Finland  Hospital District of Helsinki and Uusimaa, Helsinki, finland  Terhi Ollila  Finland	
Helsinki University Hospital and University of  Joni A Turunen  Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland  Hospital District of Helsinki and Uusimaa, Helsinki, Finland  terhi.ollila@hus.fi	
Joni A Turunen  Helsinki, Helsinki, Finland; Eye Genetics Group, Folkhälsan Research Center, Helsinki, Finland  Hospital District of Helsinki and Uusimaa, Helsinki, Finland  terhi.ollila@hus.fi	
Folkhälsan Research Center, Helsinki, Finland  Hospital District of Helsinki and Uusimaa, Helsinki, Finland  terhi.ollila@hus.fi	
Terhi Ollila Hospital District of Helsinki and Uusimaa, Helsinki, Finland terhi.ollila@hus.fi	
Terhi Ollila terhi.ollila@hus.fi Finland	
Finland	
Hannu Uusitalo Pirkanmaa Hospital District, Tampere, Finland hannu.uusitalo@tuni.fi	
Institute for Molecular Medicine Finland (FIMM),	
Juha Karjalainen juha karjalainen@helsinki.fi HiLIFE, University of Helsinki, Helsinki, Finland	
Institute for Molecular Medicine Finland (FIMM),	
Esa Pitkänen esa.pitkanen@helsinki.fi HiLIFE, University of Helsinki, Helsinki, Finland	
Mengzhen Liu Abbvie, Chicago, IL, United States mengzhen.liu@abbvie.com	
Heiko Runz Biogen, Cambridge, MA, United States heiko.runz@biogen.com	
Stephanie Loomis Biogen, Cambridge, MA, United States stephanie.loomis@biogen.com	
Erich Strauss Genentech, San Francisco, CA, United States strauss.erich@gene.com	
Natalie Bowers Genentech, San Francisco, CA, United States bowersn1@gene.com	
Rion Pendergrass Genentech, San Francisco, CA, United States penders2@gene.com	
Kaisa Tasanen Northern Ostrobothnia Hospital District, Oulu, kaisa.tasanen-maatta@oulu.fi	
Finland	
Northern Ostrobothnia Hospital District, Oulu, Laura Huilaja laura.huilaja@oulu.fi	
Finland	
Hospital District of Helsinki and Uusimaa, Helsinki, katariina.hannula-jouppi@hus.fi	
Finland	
Teea Salmi Pirkanmaa Hospital District, Tampere, Finland teea.salmi@pshp.fi	
Hospital District of Southwest Finland, Turku, Sirkku Peltonen sipelto@utu.fi	
Finland	
Hospital District of Southwest Finland, Turku, Leena Koulu leena.koulu@tyks.fi	
Finland	
Nizar Smaoui Abbvie, Chicago, IL, United States nizar.smaoui@abbvie.com	
Fedik Rahimov Abbvie, Chicago, IL, United States fedik.rahimov@abbvie.com	
Anne Lehtonen Abbvie, Chicago, IL, United States anne.lehtonen@abbvie.com	

David Choy	Genentech, San Francisco, CA, United States	choy.david@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com
Ying Wu	Pfizer, New York, NY, United States	ying.wu3@pfizer.com
Pirkko Pussinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pirkko.pussinen@helsinki.fi
Aino Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	aino.m.salminen@helsinki.fi
Tuula Salo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.salo@helsinki.fi
David Rice	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	david.rice@helsinki.fi
Pekka Nieminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pekka.nieminen@helsinki.fi
Ulla Palotie	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ulla.palotie@helsinki.fi
Maria Siponen	Northern Savo Hospital District, Kuopio, Finland	maria.siponen@uef.fi
Liisa Suominen	Northern Savo Hospital District, Kuopio, Finland	liisa.suominen@uef.fi
Päivi Mäntylä	Northern Savo Hospital District, Kuopio, Finland	paivi.mantyla@uef.fi
Ulvi Gursoy	Hospital District of Southwest Finland, Turku, Finland	ulvi.gursoy@utu.fi
Vuokko Anttonen	Northern Ostrobothnia Hospital District, Oulu, Finland	vuokko.anttonen@oulu.fi
Kirsi Sipilä	Research Unit of Oral Health Sciences Faculty of Medicine, University of Oulu, Oulu, Finland;  Medical Research Center, Oulu, Oulu University  Hospital and University of Oulu, Oulu, Finland	kirsi.sipila@oulu.fi
Rion Pendergrass	Genentech, San Francisco, CA, United States	pendergrass.sarah@gene.com
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laivuori@helsinki.fi
Venla Kurra	Pirkanmaa Hospital District, Tampere, Finland	venla.kurra@tuni.fi
Laura Kotaniemi-Talonen	Pirkanmaa Hospital District, Tampere, Finland	laura.kotaniemi-talonen@tuni.fi
Oskari Heikinheimo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	oskari.heikinheimo@helsinki.fi
likka Kalliala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ilkka.kalliala@hus.fi
Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki,	lauri.aaltonen@helsinki.fi

Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com
Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu@abbvie.com
Natalia Pujol	Estonian biobank, Tartu, Estonia	natalia.pujolgualdo@oulu.fi
Triin Laisk	Estonian biobank, Tartu, Estonia	triin.laisk@ut.ee
Susanna Savukoski	University of Oulu, Oulu, Finland	susanna.savukoski@oulu.fi
Riikka Arffman	University of Oulu, Oulu, Finland	riikka.arffman@oulu.fi
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi
Heidi Silven	University of Oulu, Oulu, Finland	heidi.silven@student.oulu.fi
Jaakko Tyrmi	Tampere, Tampere, Finland	jaakko.tyrmi@oulu.fi
	University of Oulu, Oulu, Finland / University of	
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi
Niko Välimäki	General Hospital University of Helsinki, Helsinki, Finland	niko.valimaki@helsinki.fi
	Broad Institute of MIT and Harvard; Massachusetts	
Mark Daly	HiLIFE, University of Helsinki, Helsinki, Finland;	mark.daly@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
	HiLIFE, University of Helsinki, Helsinki, Finland	
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM),	mary.reeve@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM),	taru.tukiainen@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	S. S
Elisabeth Widen	Institute for Molecular Medicine Finland (FIMM),	elisabeth.widen@helsinki.fi
Katja Kivinen	HiLIFE, University of Helsinki, Helsinki, Finland	katja.kivinen@helsinki.fi
Katia Kivinon	Institute for Molecular Medicine Finland (FIMM),	katia kivinan@halsinki fi
Terhi Piltonen	Finland	terhi.piltonen@oulu.fi
T. J. Dille	Northern Ostrobothnia Hospital District, Oulu,	
Maarit Niinimäki	Finland	maarit.niinimaki@oulu.fi
	Northern Ostrobothnia Hospital District, Oulu,	
Laure Morin-Papunen	Finland	Imp@cc.oulu.fi
	Northern Ostrobothnia Hospital District, Oulu,	
Outi Uimari	Northern Ostrobothnia Hospital District, Oulu, Finland	outi.uimari@oulu.fi
	Finland	
Marja Vääräsmäki	Northern Ostrobothnia Hospital District, Oulu,	marja.vaarasmaki@oulu.fi
Contamino Rottanon	Finland	onamos.rotanone outa.n
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu,	Johannes.Kettunen@oulu.fi
	Finland	varpu.jokimaa@utu.fi
Varpu Jokimaa		

Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Janet Kumar	GlaxoSmithKline, Collegeville, PA, United States	janet.x.kumar@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
liris Hovatta	University of Helsinki, Finland	iiris.hovatta@helsinki.fi
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com
Erkki Isometsä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	erkki.isometsa@hus.fi
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollila@helsinki.fi
Jaana Suvisaari	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	jaana.suvisaari@thl.fi
Antti Mäkitie	Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland	antti.makitie@helsinki.fi
Argyro Bizaki-Vallaskangas	Pirkanmaa Hospital District, Tampere, Finland	argyro.bizaki-vallaskangas@tuni.fi
Sanna Toppila-Salmi	University of Eastern Finland and Kuopio University Hospital, Department of Otorhinolaryngology, Kuopio, Finland and Department of Allergy, Helsinki University Hospital and University of Helsinki, Finland	sanna.salmi@helsinki.fi
Tytti Willberg	Hospital District of Southwest Finland, Turku, Finland	tytti.willberg@tyks.fi
Elmo Saarentaus	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarentaus@helsinki.fi
Antti Aarnisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	antti.aarnisalo@hus.fi
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi
Elisa Rahikkala	Northern Ostrobothnia Hospital District, Oulu, Finland	elisa.rahikkala@ppshp.fi
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kettunen@oulu.fi
Kristiina Aittomäki	Department of Medical Genetics, Helsinki University Central Hospital, Helsinki, Finland	kristiina.aittomaki@helsinki.fi
Fredrik Åberg	Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki University, Helsinki, Finland	fredrik.aberg@helsinki.fi
Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland;	mkurki@broadinstitute.org

	Drood Institute Combridge MAA United Oters	T
	Broad Institute, Cambridge, MA, United States	
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM),	samuli.ripatti@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
	Institute for Molecular Medicine, Finland (FIMM),	
Mark Daly	HiLIFE, University of Helsinki, Helsinki, Finland;	mark.daly@helsinki.fi
	Broad Institute of MIT and Harvard; Massachusetts	
	General Hospital	
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM),	juha.karjalainen@helsinki.fi
Julia Karjalalileli	HiLIFE, University of Helsinki, Helsinki, Finland	juna.karjalamenemenisinki.ii
	Institute for Molecular Medicine Finland (FIMM),	
	HiLIFE, University of Helsinki, Helsinki, Finland;	
Aki Havulinna	Finnish Institute for Health and Welfare (THL),	aki.havulinna@helsinki.fi
	Helsinki, Finland	
	Institute for Molecular Medicine Finland (FIMM),	
Juha Mehtonen	HiLIFE, University of Helsinki, Helsinki, Finland	juha.mehtonen@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Priit Palta	HiLIFE, University of Helsinki, Helsinki, Finland	priit.palta@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Shabbeer Hassan	HiLIFE, University of Helsinki, Helsinki, Finland	shabbeer.hassan@helsinki.fi
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM),	nietro della briattana rala @balainki fi
Pietro Della Briotta Paroto	HiLIFE, University of Helsinki, Helsinki, Finland	pietro.dellabriottaparolo@helsinki.fi
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM),	shabbeer.hassan@helsinki.fi
Shabbeer Hassan	HiLIFE, University of Helsinki, Helsinki, Finland	Shabbeer.nassan@heisinki.ii
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM),	susanna.lemmela@helsinki.fi
Susailla Lellilleia	HiLIFE, University of Helsinki, Helsinki, Finland	Susailia.lettiitiela@fielsiiki.li
Manuel Rivas	University of Stanford, Stanford, CA, United States	mrivas@stanford.edu
Aarno Palotie	Institute for Molecular Medicine Finland (FIMM),	aarno.palotie@helsinki.fi
Admor diode	HiLIFE, University of Helsinki, Helsinki, Finland	damo.paiotic@noisinki.ii
Aoxing Liu	Institute for Molecular Medicine Finland (FIMM),	acting live halainti fi
Aoxing Liu	HiLIFE, University of Helsinki, Helsinki, Finland	aoxing.liu@helsinki.fi
Arto Lahisto	Institute for Molecular Medicine Finland (FIMM),	arto lehisto@holsinki fi
Arto Lehisto	HiLIFE, University of Helsinki, Helsinki, Finland	arto.lehisto@helsinki.fi
A. I. O. O.	Institute for Molecular Medicine Finland (FIMM),	
Andrea Ganna	HiLIFE, University of Helsinki, Helsinki, Finland	aganna@broadinstitute.org
	Institute for Molecular Medicine Finland (FIMM),	
Vincent Llorens	HiLIFE, University of Helsinki, Helsinki, Finland	vincent.llorens@helsinki.fi
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM),	hannele.laivuori@helsinki.fi

	HiLIFE, University of Helsinki, Helsinki, Finland	
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	taru.tukiainen@helsinki.fi
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi
Henrike Heyne	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hheyne@broadinstitute.org
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi
Joel Rämö	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	joel.ramo@helsinki.fi
Elmo Saarentaus	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarentaus@helsinki.fi
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollila@helsinki.fi
Rodos Rodosthenous	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	rodos.rodosthenous@helsinki.fi
Satu Strausz	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	satu.strausz@helsinki.fi
Tuula Palotie	University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.palotie@helsinki.fi
Kimmo Palin	University of Helsinki, Helsinki, Finland	kimmo.palin@helsinki.fi
Javier Garcia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskinen@helsinki.fi
Jiwoo Lee	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	jiwoo.lee@helsinki.fi
Kristin Tsuo	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, United States	kristintsuo@fas.harvard.edu
Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston, MA, USA	aelliott@broadinstitute.org
Kati Kristiansson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	kati.kristiansson@thl.fi

	Finnish Red Cross Blood Service / Finnish	
Mikko Arvas	Hematology Registry and Clinical Biobank,	mikko.arvas@veripalvelu.fi
	Helsinki, Finland	
Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland	kati.hyvarinen@veripalvelu.fi
Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland	jarmo.ritari@veripalvelu.fi
	Helsinki Biobank / Helsinki University and Hospital	
Olli Carpén	District of Helsinki and Uusimaa, Helsinki	olli.carpen@helsinki.fi
	Northern Finland Biobank Borealis / University of	
Johannes Kettunen	Oulu / Northern Ostrobothnia Hospital District,	johannes.kettunen@oulu.fi
	Oulu, Finland	,
Katri Pylkäs	University of Oulu, Oulu, Finland	katri.pylkas@oulu.fi
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi
Minna Karjalainen	University of Oulu, Oulu, Finland	minna.k.karjalainen@oulu.fi
	Northern Finland Biobank Borealis / University of	
Tuomo Mantere	Oulu / Northern Ostrobothnia Hospital District,	tuomo.mantere@oulu.fi
ruomo mantere	Oulu, Finland	tuomo.mantere@outu.n
	Finnish Clinical Biobank Tampere / University of	
Eeva Kangasniemi		eeva.kangasniemi@pshp.fi
Eeva Kangasilleiili	Tampere / Pirkanmaa Hospital District, Tampere,	eeva.kangasmemi@psnp.n
Const Heildings	Finland	and beitting on the
Sami Heikkinen	University of Eastern Finland, Kuopio, Finland	sami.heikkinen@uef.fi
A.d. Marrison	Biobank of Eastern Finland / University of Eastern	@ 45°
Arto Mannermaa	Finland / Northern Savo Hospital District, Kuopio,	arto.mannermaa@uef.fi
<u></u>	Finland	
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi
Nina Pitkänen	Auria Biobank / University of Turku / Hospital	Niina.Pitkanen@tyks.fi
	District of Southwest Finland, Turku, Finland	
Samuel Lessard	Translational Sciences, Sanofi R&D, Framingham,	samuel.lessard@sanofi.com
	MA, USA	
Clément Chatelain	Translational Sciences, Sanofi R&D, Framingham,	clement.chatelain@sanofi.com
	MA, USA	
Lila Kallio	Auria Biobank / University of Turku / Hospital	Lila.Kallio@tyks.fi
	District of Southwest Finland, Turku, Finland	
Tiina Wahlfors	THL Biobank / Finnish Institute for Health and	tiina.wahlfors@thl.fi
	Welfare (THL), Helsinki, Finland	
Jukka Partanen	Finnish Red Cross Blood Service / Finnish	
	Hematology Registry and Clinical Biobank,	jukka.partanen@veripalvelu.fi
	Helsinki, Finland	
Foro Dunkko	Helsinki Biobank / Helsinki University and Hospital	
Eero Punkka		eero.punkka@hus.fi

Raisa Serpi	Oulu / Northern Ostrobothnia Hospital District, Oulu, Finland	raisa.serpi@ppshp.fi
	Oulu, Finland	
	Finnish Clinical Biobank Tampere / University of	
Sanna Siltanen	Tampere / Pirkanmaa Hospital District, Tampere,	sanna.siltanen@pshp.fi
	Finland	
	Biobank of Eastern Finland / University of Eastern	
Veli-Matti Kosma	Finland / Northern Savo Hospital District, Kuopio,	veli-matti.kosma@uef.fi
	Finland	
	Central Finland Biobank / University of Jyväskylä /	
Teijo Kuopio	Central Finland Health Care District, Jyväskylä,	teijo.kuopio@ksshp.fi
	Finland	
Anu Jalanko	Institute for Molecular Medicine Finland (FIMM),	any interke@halainki fi
Anu Jaianko	HiLIFE, University of Helsinki, Helsinki, Finland	anu.jalanko@helsinki.fi
Huei-Yi Shen	Institute for Molecular Medicine Finland (FIMM),	huei-yi.shen@helsinki.fi
nuel-11 Sileti	HiLIFE, University of Helsinki, Helsinki, Finland	nuel-yl.shen@nelshki.ii
Risto Kajanne	Institute for Molecular Medicine Finland (FIMM),	risto.kajanne@helsinki.fi
Nisto Najarine	HiLIFE, University of Helsinki, Helsinki, Finland	nsto.kajanne enelsinki.n
Mervi Aavikko	Institute for Molecular Medicine Finland (FIMM),	mervi.aavikko@helsinki.fi
IVICI VI AAVIRRO	HiLIFE, University of Helsinki, Helsinki, Finland	mervi.aavinno@neisiini.ii
Helen Cooper	Institute for Molecular Medicine Finland (FIMM),	helen.cooper@helsinki.fi
Полог Сосрол	HiLIFE, University of Helsinki, Helsinki, Finland	noish.cooper@noishik.iii
Denise Öller	Institute for Molecular Medicine Finland (FIMM),	denise.oller@helsinki.fi
Defined Office	HiLIFE, University of Helsinki, Helsinki, Finland	defined.one e ficialitiki.ii
	Institute for Molecular Medicine Finland (FIMM),	
Rasko Leinonen	HiLIFE, University of Helsinki, Helsinki, Finland;	rasko@ebi.ac.uk
Nasko Editorion	European Molecular Biology Laboratory, European	
	Bioinformatics Institute, Cambridge, UK	
	Finnish Clinical Biobank Tampere / University of	
Henna Palin	Tampere / Pirkanmaa Hospital District, Tampere,	henna.palin@pshp.fi
	Finland	
Malla-Maria Linna	Helsinki Biobank / Helsinki University and Hospital	malla-maria.linna@hus.fi
мана-мана <b>L</b> иша	District of Helsinki and Uusimaa, Helsinki	mana-mana.iinna@nus.ti
	Institute for Molecular Medicine Finland (FIMM),	
Mitja Kurki	HiLIFE, University of Helsinki, Helsinki, Finland;	mkurki@broadinstitute.org
	Broad Institute, Cambridge, MA, United States	
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM),	juha.karjalainen@helsinki.fi
oana Narjaiailion	HiLIFE, University of Helsinki, Helsinki, Finland	jana.narjaranore nomini.n
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM),	pietro.dellabriottaparolo@helsinki.fi

	HiLIFE, University of Helsinki, Helsinki, Finland	
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	arto.lehisto@helsinki.fi
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	juha.mehtonen@helsinki.fi
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org
Masahiro Kanai	Broad Institute, Cambridge, MA, United States	mkanai@broadinstitute.org
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org
Zhili Zheng	Broad Institute, Cambridge, MA, United States	zhengzhi@broadinstitute.org
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laivuori@helsinki.fi
Aki Havulinna	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Finnish Institute for Health and Welfare (THL), Helsinki, Finland	aki.havulinna@helsinki.fi
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lemmela@helsinki.fi
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskinen@helsinki.fi
L. Elisa Lahtela	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	laura.lahtela@helsinki.fi
Mari Kaunisto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mari.kaunisto@helsinki.fi
Elina Kilpeläinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elina.kilpelainen@helsinki.fi
Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	timo.p.sipila@helsinki.fi
Oluwaseun Alexander Dada	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	alexander.dada@helsinki.fi
Awaisa Ghazal	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	awaisa.ghazal@helsinki.fi
Anastasia Kytölä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	anastasia.shcherban@helsinki.fi
Rigbe Weldatsadik	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	rigbe.weldatsadik@helsinki.fi
Sanni Ruotsalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	sanni.ruotsalainen@helsinki.fi
Kati Donner	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	kati.donner@helsinki.fi

T. D. C. 111	Institute for Molecular Medicine Finland (FIMM),	
Timo P. Sipilä	HiLIFE, University of Helsinki, Helsinki, Finland	timo.p.sipila@helsinki.fi
Anu Loukola	Helsinki Biobank / Helsinki University and Hospital	anu.loukola@hus.fi
Title Eduloid	District of Helsinki and Uusimaa, Helsinki	anu.loukola@nus.ii
Päivi Laiho	THL Biobank / Finnish Institute for Health and	paivi.laiho@thl.fi
	Welfare (THL), Helsinki, Finland	
Tuuli Sistonen	THL Biobank / Finnish Institute for Health and	tuuli.sistonen@thl.fi
	Welfare (THL), Helsinki, Finland	
Essi Kaiharju	THL Biobank / Finnish Institute for Health and	essi.kaiharju@thl.fi
	Welfare (THL), Helsinki, Finland	
Markku Laukkanen	THL Biobank / Finnish Institute for Health and	markku.laukkanen@thl.fi
	Welfare (THL), Helsinki, Finland	
Elina Järvensivu	THL Biobank / Finnish Institute for Health and	elina.jarvensivu@thl.fi
	Welfare (THL), Helsinki, Finland	
Sini Lähteenmäki	THL Biobank / Finnish Institute for Health and	sini.lahteenmaki@thl.fi
	Welfare (THL), Helsinki, Finland	
Lotta Männikkö	THL Biobank / Finnish Institute for Health and	lotta.mannikko@thl.fi
	Welfare (THL), Helsinki, Finland	
Regis Wong	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	regis.wong@thl.fi
	THL Biobank / Finnish Institute for Health and	
Auli Toivola	Welfare (THL), Helsinki, Finland	auli.toivola@thl.fi
	THL Biobank / Finnish Institute for Health and	
Minna Brunfeldt	Welfare (THL), Helsinki, Finland	minna.brunfeldt@thl.fi
	THL Biobank / Finnish Institute for Health and	
Hannele Mattsson	Welfare (THL), Helsinki, Finland	hannele.mattsson@thl.fi
	THL Biobank / Finnish Institute for Health and	kati.kristiansson@thl.fi
Kati Kristiansson	Welfare (THL), Helsinki, Finland	
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM),	susanna.lemmela@helsinki.fi
Susaima Lemmera	HiLIFE, University of Helsinki, Helsinki, Finland	
Sami Koskelainen	THL Biobank / Finnish Institute for Health and	sami.koskelainen@thl.fi
outil Roskcialier	Welfare (THL), Helsinki, Finland	
Tero Hiekkalinna	THL Biobank / Finnish Institute for Health and	tero.hiekkalinna@helsinki.fi
	Welfare (THL), Helsinki, Finland	
Teemu Paajanen	THL Biobank / Finnish Institute for Health and	teemu.paajanen@thl.fi
,	Welfare (THL), Helsinki, Finland	
Priit Palta	Institute for Molecular Medicine Finland (FIMM),	priit.palta@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Shuang Luo	Institute for Molecular Medicine Finland (FIMM),	shuang.luo@helsinki.fi

	HiLIFE, University of Helsinki, Helsinki, Finland	
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi
Shanmukha Sampath	Institute for Molecular Medicine Finland (FIMM),	sam.padmanabhuni@helsinki.fi
Padmanabhuni	HiLIFE, University of Helsinki, Helsinki, Finland	sam.paumanabhum@neisinki.n
Marianna Niemi	University of Tampere, Tampere, Finland	marianna.niemi@tuni.fi
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi
Javier Gracia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi
Mika Helminen	University of Tampere, Tampere, Finland	mika.helminen@tuni.fi
Tiina Luukkaala	University of Tampere, Tampere, Finland	tiina.luukkaala@tuni.fi
lida Vähätalo	University of Tampere, Tampere, Finland	iida.vahatalo@epshp.fi
Jyrki Tammerluoto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	jyrki.tammerluoto@helsinki.fi
Marco Hautalahti	Finnish Biobank Cooperative - FINBB	marco.hautalahti@finbb.fi
Johanna Mäkelä	Finnish Biobank Cooperative - FINBB	johanna.makela@finbb.fi
Sarah Smith	Finnish Biobank Cooperative - FINBB	sarah.smith@finbb.fi
Tom Southerington	Finnish Biobank Cooperative - FINBB	tom.southerington@finbb.fi
Petri Lehto	Finnish Biobank Cooperative - FINBB	petri.lehto@finbb.fi